Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to Buy at ValuEngine

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday, ValuEngine reports.

A number of other equities analysts also recently weighed in on AUPH. Oppenheimer initiated coverage on shares of Aurinia Pharmaceuticals in a research note on Tuesday, September 10th. They set an “outperform” rating and a $14.00 price target on the stock. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Royal Bank of Canada reaffirmed a “buy” rating and set a $11.00 price target on shares of Aurinia Pharmaceuticals in a research note on Thursday, August 8th. Bloom Burton reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 2nd. Finally, Citigroup initiated coverage on shares of Aurinia Pharmaceuticals in a research note on Monday, September 9th. They set an “outperform” rating and a $14.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average target price of $15.18.

NASDAQ:AUPH opened at $4.11 on Thursday. The company has a market cap of $387.04 million, a P/E ratio of -5.40 and a beta of 1.11. Aurinia Pharmaceuticals has a fifty-two week low of $3.52 and a fifty-two week high of $7.85. The firm’s 50 day moving average is $5.67 and its two-hundred day moving average is $6.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. As a group, research analysts anticipate that Aurinia Pharmaceuticals will post -0.68 earnings per share for the current year.

Several hedge funds have recently modified their holdings of AUPH. Vivo Capital LLC raised its stake in shares of Aurinia Pharmaceuticals by 57.7% in the 2nd quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock valued at $12,592,000 after acquiring an additional 700,333 shares during the period. Orbimed Advisors LLC raised its stake in shares of Aurinia Pharmaceuticals by 12.1% in the 2nd quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock valued at $23,234,000 after acquiring an additional 381,192 shares during the period. Redmile Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $2,101,000. BlackRock Inc. raised its stake in shares of Aurinia Pharmaceuticals by 3.1% in the 2nd quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock valued at $6,063,000 after acquiring an additional 28,129 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Aurinia Pharmaceuticals by 35.5% in the 2nd quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock valued at $513,000 after acquiring an additional 20,432 shares during the period. 31.96% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: Trading on Margin

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.